Pre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinoma

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1181-1188

  Nishikawa, Hiroki ^a   Arimoto, Akira ^a   Wakasa, Tomoko ^a   Kita, Ryuichi ^a   Kimura, Toru ^a   Osaki, Yukio ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

C Reactive protein; Hepatocellular carcinoma; Prognostic factor; Surgical resection

Indexed keywords

C REACTIVE PROTEIN;

ABSCESS; ACUTE HEART FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ASCITES; ASPIRATION PNEUMONIA; BILE LEAKAGE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL;

AGED; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; CAUSE OF DEATH; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 84875888427     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Livraghi T, Makisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg 100: 22-29, 2011.
2. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273, 2012.
3. Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY and Wu MC: A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 249: 195-202, 2009.
4. Nishikawa H, Osaki Y, Kita R, Kimura T, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S and Nasu A: Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence. Int J Oncol 41: 903-909, 2012.
5. de Lope CR, Tremosini S, Forner A, Reig M and Bruix J: Management of HCC. J Hepatol 56: S75-S87, 2012.
6. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH and Dematteo RP: Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 249: 617-623, 2009.
7. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K and Yamaoka Y: Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101: 796-802, 2004.
8. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM and Wong J: Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 234: 63-70, 2001.
9. Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ and Lam VW: Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB 14: 285-290, 2012.
10. Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, Chung AY, Ooi LL and Tan SB: Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg 254: 108-113, 2011.
11. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N and Makuuchi M: Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134: 1908-1916, 2008.
12. Zhou L, Liu C, Meng FD, Qu K, Tian F, Tai MH, Wei JC and Wang RT: Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pac J Cancer Prev 13: 483-486, 2012.
13. Morris-Stiff G, Gomez D and Prasad KR: C-Reactive protein in liver cancer surgery. Eur J Surg Oncol 34: 727-729, 2008.
14. Sieghart W, Pinter M, Hucke F, Graziadei I, Schoniger-Hekele M, Muller C, Vogel W, Trauner M and Peck-Radosavljevic M: A single determination of C-reactive protein at the time of diagnosis predicts long term outcome of patients with hepatocellular carcinoma. Hepatology 2012 Sep 7. [Epub ahead of print]
15. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R and Heinrich PC: Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12: 1179-1186, 1990.
16. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444. 2008.
17. Allin KH and Nordestgaard BG: Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48: 155-170, 2011
18. Nozoe T, Matsumata T, Kitamura M and Sugimachi K: Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335-338, 1998.
19. Jiang X, Hiki N, Nunobe S, Kumagai K, Kubota T, Aikou S, Sano T and Yamaguchi T: Prognostic importance of the inflammationbased Glasgow prognostic score in patients with gastric cancer. Br J Cancer 107: 275-279, 2012.
20. Zingg U, Forberger J, Rajcic B, Langton C and Jamieson GG: Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg 14: 462-469, 2010.
21. Saito K and Kihara K: C-Reactive protein as a biomarker for urological cancers. Nat Rev Urol 8: 659-666, 2011.
22. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM and Rahemtulla A: Soluble receptor activator of nuclear factor kappaB ligandosteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064-1069, 2003.
23. Chun JM, Kwon HJ, Sohn J, Kim SG, Park JY, Bae HI, Yun YK and Hwang YJ: Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol 103: 148-151, 2011.
24. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M and Sawada T: Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. J Surg Oncol 103: 801-806, 2011.
25. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K and Takenaka K: The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103: 1856-1864, 2005.
26. Bruix J and Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
27. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K and Okita K: Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer 91: 1342-1348, 2001.
28. Liver Cancer Study Group of Japan: The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 19: 98-129, 1989.
29. Hu BS, Chen K, Tan HM, Ding XM and Tan JW: Comparison of laparoscopic vs. open liver lobectomy (segmentectomy) for hepatocellular carcinoma. World J Gastroenterol 17: 4725-4728, 2011.
30. Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Henmi S, Sakamoto A, Ishikawa T, Saito S, Kita R and Kimura T: Branched-chain amino acid treatment before transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 18: 1379-1384, 2012.
31. Gomez-Rodriguez R, Romero-Gutierrez M, Artaza-Varasa T, Gonzalez-Frutos C, Ciampi-Dopazo JJ, de-la-Cruz-Perez G and Sanchez-Ruano JJ: The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. Rev Esp Enferm Dig 104: 298-304, 2012.